ALKS Alkermes plc
$45.97▼ -0.30%
Healthcare
Other
After hours
$45.97▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.22M
Avg Volume (10D) 1.39M
Key Metrics & Fundamentals
Market Cap
$7.71B
P/E Ratio
121.0
Div Yield
–%
52W Range
26.40 - 55.67
% vs 50 MA
-8.05%
% vs 200 MA
20.81%
RSI-14
37.9
MACD Histogram
-0.2000
Beta (1Y vs SPY)
0.78
Free Cash Flow
-$169.83M
Gross Rev
$392.91M
Gross Profit
$331.33M
EBITDA
-$21.61M
COGS
$61.58M
Operating Exp
$379.61M
Operating Income
-$48.28M
EBIT
-$48.28M
Pretax Income
-$61.93M
Net Income
-$66.48M
EPS (Diluted)
-0.40
Price & Volume History
Loading chart…
Recent News
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Business Wire · Sep 10, 2026 11:00 AM
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Motley Fool · Aug 29, 2026 7:00 PM
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Zacks · Aug 27, 2026 3:30 PM
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Business Wire · Aug 24, 2026 10:30 PM
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Zacks · Aug 21, 2026 4:40 PM
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Zacks · Aug 21, 2026 2:48 PM
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Zacks · Aug 12, 2026 3:22 PM
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
Insider Monkey · Aug 11, 2026 12:22 PM
The Race to Come Up With the Next Big Sleep Drug
The Wall Street Journal · Aug 6, 2026 6:30 PM
Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing
MT Newswires · Aug 4, 2026 7:47 AM
Financial Overview - Income Statement
Quarterly
Mar 2026
See ALKS's money flow as a full page
Social Sentiment
Avg +0.05 · 2 posts
NewsTradeMarket Close Report - Tuesday, March 31, 2026
r/investing · Mar 31, 2026
Positive price increase indicates positive sentiment.
positive
+0.70
DDDiscussionWhy $NMRA is going to tank 70% year end
r/wallstreetbets · Oct 21, 2024
The post discusses the failure of ALKS-5461, a competing drug.
negative
-0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.